Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-PTX, S-1, and Sintilimab in Stage IIIC Gastric Cancer
NCT04781413Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric cancer (GC), sponsored by Ruijin Hospital. Primary endpoints: Recommended Dose, Safety and 1 more. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04781413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781413.